Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation

Journal of Clinical Pharmacology

Volumn 48, Issue 9, 2008, Pages 1052-1062

  Johnson, L'Aurelle ^a   Orchard, Paul J ^b   Baker, K Scott ^b   Brundage, Richard ^a   Cao, Qing ^c   Wang, Xinjing ^b   Langer, Erica ^b   Farag El Maasah, Sharein ^a   Ross, Julie A ^b   Remmel, Rory ^a   Jacobson, Pamala A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Busulfan; Glutathione S transferase; Pharmacokinetics; Polymorphisms

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; FOSPHENYTOIN SODIUM; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; AGE; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG METABOLISM; DRUG SAFETY; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GSTA1 GENE; GSTM1 GENE; GSTP1 GENE; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; METACHROMATIC LEUKODYSTROPHY; MONTE CARLO METHOD; MORTALITY; RETROSPECTIVE STUDY; SEIZURE; STATISTICAL ANALYSIS; STEM CELL TRANSPLANTATION; UMBILICAL CORD BLOOD; VEIN OCCLUSION; WEIGHT;

ADOLESCENT; AGE FACTORS; BODY WEIGHT; BUSULFAN; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; FEMALE; GENETIC VARIATION; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; MYELOABLATIVE AGONISTS; PHENOTYPE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 49649127378     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008321940     Document Type: Article

References (37)

1. McCune JS, Gooley T., Gibbs JP, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002 ; 30: 167-173.
2. Vassal G., Koscielny S., Challine D., et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1996 ; 37: 247-253.
3. Andersson BS, Thall PF, Madden T., et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002 ; 8: 477-485.
4. McCune JS, Gibbs JP, Slattery JT Plasma concentration monitoring of busulfan: does it improve clinical outcome ? Clin Pharmacokinet. 2000 ; 39: 155-165.
5. Copelan EA, Bechtel TP, Avalos BR, et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant. 2001 ; 27: 1121-1124.
6. Slattery JT, Risler LJ Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit. 1998 ; 20: 543-549.
7. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997 ; 89: 3055-3060.
8. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996 ; 17: 225-230.
9. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995 ; 16: 31-42.
10. Grochow LB Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol. 1993 ; 20: 18-25 ; quiz 26.
11. Bolinger AM, Zangwill AB, Slattery JT, et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant. 2000 ; 25: 925-930.
12. Gibbs JP, Liacouras CA, Baldassano RN, Slattery JT Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos. 1999 ; 27: 1466-1469.
13. Gibbs JP, Murray G., Risler L., Chien JY, Dev R., Slattery JT Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res. 1997 ; 57: 5509-5516.
14. Hassan M., Ljungman P., Bolme P., et al. Busulfan bioavailability. Blood. 1994 ; 84: 2144-2150.
15. Czerwinski M., Gibbs JP, Slattery JT Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996 ; 24: 1015-1019.
16. Gibbs JP, Czerwinski M., Slattery JT Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res. 1996 ; 56: 3678-3681.
17. Hu X., Pal A., Krzeminski J., et al. Specificities of human glutathione S-transferase isozymes toward anti-diol epoxides of methylchrysenes. Carcinogenesis. 1998 ; 19: 1685-1689.
18. Srivastava A., Poonkuzhali B., Shaji RV, et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004 ; 104: 1574-1577.
19. Kusama M., Kubota T., Matsukura Y., et al. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta. 2006 ; 368: 93-98.
20. Lai WK, Pang CP, Law LK, Wong R., Li CK, Yuen PM Routine analysis of plasma busulfan by gas chromatography-mass fragmentography. Clin Chem. 1998 ; 44: 2506-2510.
21. Busulfex [package insert]. Redwood City, CA: PDL Bio Pharma, Inc ; 2007.
22. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987 ; 44: 778-783.
23. Dalle JH, Wall D., Theoret Y., et al. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results. Bone Marrow Transplant. 2003 ; 32: 647-651.
24. Booth BP, Rahman A., Dagher R., et al. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. J Clin Pharmacol. 2007 ; 47: 101-111.
25. Vassal G., Michel G., Esperou H., et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol. 2008 ; 61: 113-123.
26. Nguyen L., Fuller D., Lennon S., Leger F., Puozzo C. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant. 2004 ; 33: 979-987.
27. Robert J., Morvan VL, Smith D., Pourquier P., Bonnet J. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol. 2005 ; 54: 171-196.
28. Garte S., Gaspari L., Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev. 2001 ; 10: 1239-1248.
29. Takama H., Tanaka H., Nakashima D., Ueda R., Takaue Y. Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006 ; 37: 345-351.
30. Cremers S., Schoemaker R., Bredius R., et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol. 2002 ; 53: 386-389.
31. Schechter T., Finkelstein Y., Doyle J., et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007 ; 13: 307-314.
32. Zwaveling J., Bredius RG, Cremers SC, et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant. 2005 ; 35: 17-23.
33. Shaw PJ, Scharping CE, Brian RJ, Earl JW Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood. 1994 ; 84: 2357-2362.
34. Poonkuzhali B., Chandy M., Srivastava A., Dennison D., Krishnamoorthy R. Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos. 2001 ; 29: 264-267.
35. Coles BF, Morel F., Rauch C., et al. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics. 2001 ; 11: 663-669.
36. Kashyap A., Wingard J., Cagnoni P., et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002 ; 8: 493-500.
37. Bredschneider M., Klein K., Murdter TE, et al. Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. Clin Pharmacol Ther. 2002 ; 71: 479-487.